5/9/2025

Janusmed kön och genus

Janusmed kön och genus – Ranitidin Apofri

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ranitidin

Ranitidin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.

  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.

  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.

  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.

  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.

  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.

  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.

  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.

  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.
  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.
  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.
  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.
  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.
  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.
  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.
  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.
  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]